Departamento de Anatomia Patològica, Vall d'Hebron Hospital Universitari, Barcelona Hospital Campus, Barcelona, Spain; Grupo de Patología Molecular, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain; Universitat Autònoma de Barcelona, Bellaterra, Spain.
Servicio de Anatomía Patológica, Hospital Universitario Virgen del Rocío, Sevilla (Spain); Centro de Investigacion Biomédica en Red en Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
Future Oncol. 2021 Apr;17(10):1209-1218. doi: 10.2217/fon-2020-1100. Epub 2020 Dec 8.
Triple-negative breast cancer (TNBC) is more aggressive than other breast cancer subtypes. TNBC is characterized by increased expression of Programmed Death-ligand 1 (PD-L1), a signal used by many tumors to escape the immune response. Expression of PD-L1 is a positive predictor of response to immunotherapy; therefore, it should be investigated in TNBC in order to select patients who may benefit from anti-PD-L1 therapies. While many PD-L1 assays are available, only the VENTANA platform with the anti-PD-L1 (SP142) antibody is licensed as a companion diagnostic device for selecting patients with metastatic/advanced TNBC who are candidates for treatment with atezolizumab. In this article, we provide a summary of an expert round-table discussion about PD-L1 testing, using the SP142 antibody in metastatic TNBC.
三阴性乳腺癌（TNBC）比其他乳腺癌亚型更具侵袭性。TNBC 的特征是程序性死亡配体 1（PD-L1）的表达增加，许多肿瘤利用 PD-L1 来逃避免疫反应。PD-L1 的表达是对免疫疗法反应的阳性预测指标；因此，应该在 TNBC 中进行调查，以便选择可能受益于抗 PD-L1 治疗的患者。虽然有许多 PD-L1 检测方法，但只有 VENTANA 平台上的抗 PD-L1（SP142）抗体被许可作为选择转移性/晚期 TNBC 患者的伴随诊断设备，这些患者适合接受阿特珠单抗治疗。在本文中，我们提供了一个专家圆桌讨论的总结，内容是关于使用 SP142 抗体检测转移性 TNBC 中的 PD-L1。
